Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Crescent Biopharma, Inc.
crescentbiopharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Crescent Biopharma secured funding through a public offering of approximately 8.1 million ordinary shares via an underwriting agreement with Jefferies LLC and TD Securities, providing capital to advance its therapeutic development initiatives.
Key Takeaways
Crescent Biopharma executed an underwriting agreement for a public offering of 8,094,793 ordinary shares on July 14, 2026
Jefferies LLC and TD Securities (USA) LLC are the underwriters for this capital raise
2 more takeaways